Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2006 Jul 19;2006(3):CD003218.
doi: 10.1002/14651858.CD003218.pub2.

Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy

D Annane  1 , D H Moore, P R J Barnes, R G Miller
Affiliations
Meta-Analysis

Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy

D Annane et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Excessive daytime sleepiness is a common symptom of myotonic dystrophy. Psychostimulants are drugs increasingly used to treat hypersomnia in myotonic dystrophy.

Objectives: To search systematically for, and combine all evidence from, randomised trials relating to the effects of psychostimulants in myotonic dystrophy patients with hypersomnia.

Search strategy: We searched the Cochrane Neuromuscular Disease Trials Register (January 2006), MEDLINE (from January 1966 to January 2006) and EMBASE (from January 1980 to January 2006) for randomised trials concerning psychostimulants in myotonic dystrophy, checked the bibliographies of identified papers and made enquiries of the authors of the papers. The search for relevant studies was updated in January 2006.

Selection criteria: We considered all randomised or quasi randomised trials that have evaluated any type of psychostimulants (versus a placebo or no treatment) in children or adults with proven myotonic dystrophy and hypersomnia.

Data collection and analysis: Potentially relevant papers were scrutinised by two authors and the selection of eligible studies was agreed by them and a third author. Data were extracted by one author and checked by a second author.

Main results: Primary outcome. One trial using a modified maintenance of wakefulness test showed an improvement by 5.70 (95% confidence intervals 0.1 to 11.3) minutes more in the modafinil than the control group. Secondary outcomes. In a double-blind crossover study of 10 participants with myotonic dystrophy, there was no difference between the selegiline and placebo periods in mean improvement in the multiple sleep latency test. Two trials, involving 60 participants in total, evaluated the efficacy and safety of modafinil in adults with myotonic dystrophy-related daytime sleepiness. The weighted mean difference on the Epworth Sleepiness Scale was -1.59 (95% confidence intervals, -2.77 to -0.42) in favour of modafinil.

Authors' conclusions: There is no evidence to support the routine use of psychostimulants to treat hypersomnia in myotonic dystrophy. There is some evidence from two studies that modafinil may improve daytime sleepiness. More randomised trials are needed to evaluate the efficacy and safety of psychostimulants.

PubMed Disclaimer

Conflict of interest statement

One of the authors (DA) was an investigator in one of the included trials (Orlikowski 2009) which was funded by the Association Française de lutte contre les Myopathies and by Lafon pharmaceutical company.

Figures

1
1
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
2
2
Forest plot of comparison: 1 Primary outcome: Maintenance of wakefulness test, outcome: 1.1 Mean improvement in the maintenance of wakefulness test.
3
3
Forest plot of comparison: 2 Secondary outcomes, outcome: 2.1 Mean improvement in the Epworth Sleepiness Scale.
4
4
Forest plot of comparison: 2 Secondary outcomes, outcome: 2.2 Mean improvement in multiple sleep latency test.
5
5
Forest plot of comparison: 2 Secondary outcomes, outcome: 2.3 Quality of life scale.
1.1
1.1. Analysis
Comparison 1 Mean improvement in the maintenance of wakefulness test, Outcome 1 Mean improvement in the maintenance of wakefulness test.
2.1
2.1. Analysis
Comparison 2 Secondary outcomes, Outcome 1 Mean improvement in the Epworth Sleepiness Scale.
2.2
2.2. Analysis
Comparison 2 Secondary outcomes, Outcome 2 Mean improvement in multiple sleep latency test.
2.3
2.3. Analysis
Comparison 2 Secondary outcomes, Outcome 3 Quality of life scale.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Antonini 1997 {published data only}
    1. Antonini G, Morino S, Fiorelli M, Fiorini M, Giubilei F. Selegiline in the treatment of hypersomnolence in myotonic dystrophy: a pilot study. Journal of Neuroscience 1997;147(2):167‐9. [MEDLINE: ] - PubMed
MacDonald 2002 {published and unpublished data}
    1. MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002;59(12):1876‐80. - PubMed
Orlikowski 2009 {published and unpublished data}
    1. Orlikowski D, Chevret S, Quera Salva MA, Laforêt P, Lofaso F, Verschueren A, et al. Modafinil for the treatment of excessive daytime sleepiness in myotonic dystrophy: a randomised, double‐blind, placebo‐controlled trial. Clinical Therapeutics 2009;31(8):1765‐73. - PubMed
Talbot 2003 {published and unpublished data}
    1. Talbot K, Stradling J, Crosby J, Hilton‐Jones D. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscular Disorders 2003;13(5):357‐64. - PubMed
Wintzen 2007 {published data only (unpublished sought but not used)}
    1. Wintzen AR, Lammers GJ, Dijk JG. Does modafinil enhance activity of patients with myotonic dystrophy?: a double‐blind placebo‐controlled crossover study. Journal of Neurology 2007;254(1):26‐8. - PMC - PubMed

Additional references

Brook 1992
    1. Brook JD, Currach ME, Harley HG, Buckler AJ, Church D, Aburatini, et al. Molecular basis of myotonic dystrophy expansion of a trinucleotide (CTG) repeat at the 3' end of a protein kinase family member. Cell 1992;68(4):799‐808. [MEDLINE: ] - PubMed
Buxton 1992
    1. Buxton J, Shelbourne P, Davies J, Jones L, Tongeren T, Aslanidis C, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 1992;355(6360):547‐8. [MEDLINE: ] - PubMed
Bégin 1997
    1. Bégin P, Mathieu J, Almirall J, Grassino A. Relationship between chronic hypercapnia and inspiratory muscle weakness in myotonic dystrophy. American Journal of Respiratory and Critical Care Medicine 1997;156(1):133‐9. [MEDLINE: ] - PubMed
Carskadon 1986
    1. Carskadon MA, Dement WC, Mitler MN, Roth R, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986;9(4):519‐24. [MEDLINE: ] - PubMed
Damian 2001
    1. Damian MS, Gerlach A, Schmidt F, Lehmann E, Reichman H. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001;56(6):794‐6. - PubMed
Dunne 1994
    1. Dunne PW, Walch ET, Epstein HF. Phosphorylation reactions of recombinant human myotonic dystrophy protein kinase and their inhibition. Biochemistry 1994;33(35):10809‐14. [MEDLINE: ] - PubMed
Fu 1992
    1. Fu YH, Pizzutti A, Fenwick RG Jr, King JR, Rajnarayan S, Dunne PW, et al. An unstable triplet repeat in a gene related to myotonic dystrophy. Science 1992;255(5049):1256‐8. [MEDLINE: ] - PubMed
Gillam 1964
    1. Gillam PMS, Heaf PJD, Kaufman L, Lucas BGD. Respiration in dystrophia myotonica. Thorax 1964;19:112‐20. - PMC - PubMed
Gilmartin 1991
    1. Gilmartin JJ, Cooper BG, Griffiths CJ, Walls TJ, Veale D, Stone TN, et al. Breathing during sleep in patients with myotonic dystrophy and non‐myotonic respiratory muscle weakness. Quarterly Journal of Medicine 1991;78(285):21‐31. [MEDLINE: ] - PubMed
Griggs 1989
    1. Griggs RC, Wood DS, Working Group on the Molecular Defect in Myotonic Dystrophy. Criteria for establishing the validity of genetic recombination in myotonic dystrophy. Neurology 1989;39(3):420‐1. [MEDLINE: ] - PubMed
Guilleminault 1978
    1. Guilleminault C, Cummiskey J, Motta J, Lynne‐Davies P. Respiratory and haemodynamic study during wakefulness and sleep in myotonic dystrophy. Sleep 1978;1(1):19‐31. [MEDLINE: ] - PubMed
Harley 1992
    1. Harley HG, Brook JO, Rundle SA, Crow S, Readon W, Buckler AJ, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 1992;355(6360):545‐6. [MEDLINE: ] - PubMed
Harper 1979
    1. Harper P. Myotonic Dystrophy: Major Problems in Neurology. Vol. 9, London: WB Saunders Co, 1979.
Higgins 2009
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009.. Available from www.cochrane‐handbook.org.
Hublin 1994
    1. Hulin C, Partinen N, Heinonen EH, Puuka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology 1994;44(11):2095‐101. - PubMed
Johns 1991
    1. Johns MN. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep 1991;14(6):540‐5. - PubMed
Mahadevan 1992
    1. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992;255(5049):1253‐5. [MEDLINE: ] - PubMed
Manni 1991
    1. Manni R, Zucca C, Martinetti M, Ottolini A, Lanzi G, Tartara A. Hypersomnia in dystrophia myotonica: a neurophysiological and immunogenetic study. Acta Neurologica Scandinavica 1991;84(6):498‐502. [MEDLINE: ] - PubMed
Mitler 1982
    1. Mitler MM, Gujavarty KS, Browman CP. Maintenance of wakefulness test: a polysomnographic technique for evaluating treatment in patients with excessive somnolence. Electroencephalography Clinical Neurophysiology 1982;53(6):658‐61. [MEDLINE: ] - PMC - PubMed
Ono 1998
    1. Ono S, Takahashi K, Jinnai K, Kanda F, Fukuoka Y, Kurisaki H, et al. Loss of serotonin‐containing neurons in the raphe of patients with myotonic dystrophy: a quantitative immunohistochemical study and relation to hypersomnia. Neurology 1998;50(2):535‐8. [MEDLINE: ] - PubMed
Rubinsztein 1998
    1. Rubinsztein JS, Rubinsztein DC, Goodburn S, Holland AJ. Apathy and hypersomnia are common features of myotonic dystrophy. Journal of Neurology, Neurosurgery and Psychiatry 1998;64(4):510‐5. [MEDLINE: ] - PMC - PubMed
Van der Meché 1994
    1. Meché FGA, Bogaard JM, Sluys JCM, Schimsheimer RJ, Ververs CCM, Busch HFM. Daytime sleep in myotonic dystrophy is not caused by sleep apnoea. Journal of Neurology, Neurosurgery and Psychiatry 1994;57(5):626‐8. [MEDLINE: ] - PMC - PubMed

MeSH terms

LinkOut - more resources